[Anchor]Cell Biotech, a company with 29 years of experience in probiotic development, is working on developing a colorectal cancer treatment using probiotics. This new approach is expected to overcome the limitations of existing synthetic anticancer drugs. Our reporter, Kim Hyo-sun, has the details.
[Reporter]Cell Biotech is the first company in Korea to successfully mass-produce probiotics, a feat that has made the country no longer reliant on imported probiotics. The company played a crucial role in ushering in the era of 'probiotic localization' in Korea.
Notably, Cell Biotech was the first in the world to commercialize dual-coating technology, which ensures that probiotics survive until they reach the intestines. The company is now leveraging this technology to develop an effective colorectal cancer treatment by directly delivering the drug to the intestines.
[Lee Sang-hoon / Cell Biotech CFO]"By applying the dual-coating technology, already globally recognized for its functionality in our DUOLAC® products, we were able to significantly shorten the development time. PP-P8 is a novel drug that encapsulates 29 years of research on Korean probiotics, laying the perfect foundation for core biotechnologies."
Cell Biotech’s new colorectal cancer drug, 'PP-P8,' works by inhibiting cancer cell growth and restoring the intestinal environment to a healthy state. The company discovered an anticancer protein, 'P8,' which targets and kills colorectal cancer cells, derived from 'Kimchi Probiotics.' This protein's efficacy has already been proven and published in international academic journals.
A key point of interest is that probiotics are a natural medicine with no toxicity to normal cells, focusing solely on inhibiting cancer cell growth, making the treatment much safer. Cell Biotech plans to make this new drug available as an easy-to-take oral pill and aims for large-scale production to enhance its economic viability.
[Lee Sang-hoon / Cell Biotech CFO]"P8, after penetrating colorectal cancer cells, binds to proteins involved in cancer proliferation and destroys growth-promoting proteins, thereby inhibiting the multiplication of colorectal cancer cells. Additionally, P8 has been shown to restore the intestinal environment to its normal state after microbial imbalances, a finding that has been published in Microbiome, one of the most prestigious SCI-level international journals."
Cell Biotech intends to begin Phase 1 clinical trials for this treatment in Korea by the end of this year. The company plans to complete Phase 2 trials by 2028 and obtain conditional approval for commercialization.
Reporting for Pax Economy TV, this is Kim Hyo-sun.
Source: Pax Economy TV (http://www.paxetv.com)